Topic: spinal muscular atrophy
The FDA hold on Novartis' Zolgensma IT will push the product's launch back by a year, SVB Leerink said, driving older patients to Biogen's Spinraza.
Some parents of SMA patients are worried that Biogen's Spinraza is being misclassified as an elective treatment amid COVID-19 disruptions.
Biogen isn't concerned that some providers are delaying doses of its SMA drug, though it has warned that the virus could affect future results.
Despite recent launches of rival MS drugs, Biogen is maintaining its market share, even as it spends big to prep for an expected Alzheimer's debut.
Novartis plans to give away doses of its $2.1 million gene therapy Zolgensma, but critics are worried about its 'too crude' lottery approach.
Roche's risdiplam, a potential 2020 entrant in spinal muscular atrophy, scored a FDA priority review on Monday.
The FDA halted enrollment in one arm of the phase 1/2 Strong trial, which is testing Novartis' gene therapy Zolgensma as a spinal injection.
Zolgensma hauled in $160 million in its first full quarter on the market, more than 60% above the Street's expectations.
Novartis is touting data showing dramatic improvements after treatment with Zolgensma for SMA patients between ages 2 and 5.